12 Biotech Stocks with the Biggest Upside Potential

10. Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Analyst Upside: 88.17%

Number of Hedge Fund Holders: 38

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a biotech company that discovers, develops, and delivers medicines to treat metabolic diseases. Its product portfolio includes the first and only approved oral precision medicine to treat Fabry disease, a clinical-stage treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.

The company’s total revenue for fiscal 2024 was $528 million, reflecting 32% year-over-year growth. This growth was attributed to the strong and growing demand for its products Galafold®, Pombiliti® and + Opfolda®. The company also secured reimbursement and regulatory milestones that would allow it to attain sustainable double-digital growth in 2025 and beyond.

Investors are bullish on the stock due to the increasing demand for its medicines in growing markets, accelerating profitability, strong intellectual property position, and leverageable global rare disease organization. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has the capability to expand its operations over time to become one of the leading rare disease companies. It expects continued revenue growth of around 17% to 24% in fiscal 2025, supported by the launch of Pombiliti® and Opfolda® and significant milestones in regulatory and reimbursement processes. Amicus Therapeutics, Inc. (NASDAQ:FOLD) plans to continue its growth momentum through ongoing studies and expansion of its therapeutic portfolio for rare diseases. It ranks tenth on our list.